ICICI Direct's research report on Biocon
Revenues grew 30.7% YoY to Rs 1528.8 crore (I-direct estimate: Rs 1608.0 crore) mainly due to 87.1% YoY growth in biologics to Rs 451 crore (I-direct estimate: Rs 470.0 crore). EBITDA margins improved 644 bps YoY to 26.4% (I-direct estimate: 23.6%) mainly due to strong gross margin performance (68.1% vs. 59.4% in Q4FY18). EBITDA grew 73% YoY to Rs 403 crore against I-direct estimate of Rs 378.8 crore. Adjusted net profit grew 63.9% to Rs 213.7 crore (I-direct estimate: Rs 190.0 crore) mainly due to a strong operational performance and lower tax rate (13.8% vs. 21.6% in Q4FY18).
Outlook
Biosimilar launches in developed as well as emerging markets and Syngene’s performances remain key levers for the company. On an SoTP basis, we ascribe a target price of Rs 730 per share.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
